Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, and AbbVie have entered an exclusive worldwide option and license transaction for HPN217, Harpoon’s B cell maturation antigen (BCMA)-targeting Tri-specific T cell Activating Construct (TriTAC). The companies also expanded their existing discovery collaboration for up to six additional targets. These agreements are expected to advance and broaden the use of Harpoon’s TriTAC platform, which produces novel T cell engagers targeting...